Due to the high frequency of concurrent alterations in ARID1A and PI3K pathway in some subtypes of gynecological cancers (i.e. endometriod endometrial carcinoma, clear cell ovarian cancer), we propose to combine ATR inhibitor or PARP inhibitor with PIK3CA inhibitors in a new trial to test the synergic action of these drugs. This evidence concerns the gene ARID1A and female reproductive organ cancer.